Download raw/aaer/2017/AAER-3845.txt from codewithdark/SEC-RPT-Panel: direct link, hf CLI and curl.
- Browser
- Download file 49.3 kB
-
https://huggingface.co/datasets/codewithdark/SEC-RPT-Panel/resolve/main/raw/aaer/2017/AAER-3845.txt
- Command line
-
hf download hf://datasets/codewithdark/SEC-RPT-Panel/raw/aaer/2017/AAER-3845.txt
-
curl -L -o AAER-3845.txt https://huggingface.co/datasets/codewithdark/SEC-RPT-Panel/resolve/main/raw/aaer/2017/AAER-3845.txt
49.3 kB
| UNITED STATES OF AMERICA | |
| Before the | |
| SECURITIES AND EXCHANGE COMMISSION | |
| SECURITIES ACT OF 1933 | |
| Release No. 10281 / January 18, 2017 | |
| SECURITIES EXCHANGE ACT OF 1934 | |
| Release No. 79815 / January 18, 2017 | |
| ACCOUNTING AND AUDITING ENFORCEMENT | |
| Release No. 3845 / January 18, 2017 | |
| ADMINISTRATIVE PROCEEDING | |
| File No. 3-17791 | |
| In the Matter of | |
| ORTHOFIX INTERNATIONAL N.V. | |
| Respondent. | |
| ORDER INSTITUTING CEASE-AND- | |
| DESIST PROCEEDINGS PURSUANT TO | |
| SECTION 8A OF THE SECURITIES ACT OF | |
| 1933 AND SECTION 21C OF THE | |
| SECURITIES EXCHANGE ACT OF 1934, | |
| MAKING FINDINGS, AND IMPOSING | |
| REMEDIAL SANCTIONS AND A CEASE- | |
| AND-DESIST ORDER | |
| I. | |
| The Securities and Exchange Commission (“Commission”) deems it appropriate that | |
| cease-and-desist proceedings be, and hereby are, instituted pursuant to Section 8A of the | |
| Securities Act of 1933 (“Securities Act”) and Section 21C of the Securities Exchange Act of | |
| 1934 (“Exchange Act”) against Orthofix International N.V. (“Orthofix” or “Respondent”). | |
| II. | |
| In anticipation of the institution of these proceedings, Respondent has submitted an Offer | |
| of Settlement (“Offer”) that the Commission has determined to accept. Respondent admits the | |
| facts set forth in Paragraphs 1 through 93 below, acknowledges that its conduct violated the | |
| federal securities laws, admits the Commission’s jurisdiction over it and the subject matter of | |
| these proceedings, and consents to the entry of this Order Instituting Cease-and-Desist | |
| Proceedings pursuant to Section 8A of the Securities Act of 1933 and Section 21C of the | |
| Securities Exchange Act of 1934, Making Findings, and Imposing Remedial Sanctions and a | |
| Cease-and-Desist Order (“Order”), as set forth below. | |
| 2 | |
| III. | |
| On the basis of this Order and Respondent’s Offer, the Commission finds | |
| 1 that: | |
| SUMMARY | |
| From at least 2011 to mid-2013 (“the relevant period”), Orthofix materially overstated its | |
| distributor revenue and operating income in various annual and quarterly reports and earnings | |
| releases filed with the Commission. The majority of this misconduct occurred at Orthofix’s | |
| then-largest segment, its Spine segment (“Spine”). In particular, Orthofix improperly recognized | |
| revenue associated with several transactions with Spine’s distributors, including its largest | |
| international distributor during the relevant period. Among other things, it entered into | |
| contingent sales with that distributor and also recognized revenue for product sales when the | |
| product could not be resold due to Orthofix’s delay in providing a required associated product. | |
| Moreover, in the domestic section of Spine, Orthofix improperly accounted for certain | |
| transactions by treating certain price discounts as expenses instead of a reduction to revenue and | |
| recognizing revenue on transactions in which the purchaser had the ability to return or exchange | |
| products. | |
| Orthofix’s misconduct, however, was not limited to Spine as it also improperly | |
| recognized revenue in its Orthopedics Segment through extra-contractual agreements used at its | |
| Brazilian subsidiary. Moreover, throughout the relevant period, Orthofix had inadequate internal | |
| accounting controls over its distributor revenue recognition and had a culture of setting | |
| aggressive internal sales targets and imposing pressure to meet those sales targets. | |
| As a result of its misconduct, Orthofix restated its financial results for the first quarter of | |
| fiscal year 2013, all reporting periods in fiscal years 2012 and 2011, and its annual reporting | |
| period in fiscal year 2010. For example, Orthofix announced that it had overstated its net sales | |
| for fiscal year 2011 by 6% and its operating income by over 430%. By engaging in the | |
| foregoing misconduct, Orthofix violated the antifraud, reporting, books and records, and internal | |
| accounting controls provisions of the federal securities laws, namely Sections 17(a)(2) and | |
| 17(a)(3) of the Securities Act and Sections 13(a), 13(b)(2)(A), 13(b)(2)(B) of the Exchange Act, | |
| and Rules 12b-20, 13a-1, 13a-11, and 13a-13 thereunder. | |
| RESPONDENT | |
| Orthofix International N.V. (“Orthofix”) is a company organized under the laws of | |
| Curacao and is headquartered in Lewisville, Texas. It is a diversified medical device company | |
| that develops and sells products used by doctors and other medical specialists to treat and repair | |
| human spine and orthopedic conditions. Orthofix’s common stock is registered with the | |
| Commission pursuant to Section 12(b) of the Exchange Act and trades on the NASDAQ. | |
| 1 The findings herein are made pursuant to Respondent’s Offer and are not binding on any other person or | |
| entity in this or any other proceeding. | |
| 3 | |
| Orthofix’s fiscal year ends on December 31. During the relevant period, Orthofix sold securities | |
| to its employees pursuant to Form S-8 registration statements filed with the Commission. A | |
| broad range of employees could purchase Orthofix stock in these offerings via payroll | |
| deductions. During the relevant period, the Form S-8 registration statements incorporated by | |
| reference the company’s public filings with the Commission. | |
| OTHER RELEVANT PERSONS | |
| The Spine CFO served as the Chief Financial Officer of Orthofix’s Spine Segment from | |
| July 2010 until he resigned in approximately February 2013. | |
| The Spine President served as the President of Orthofix’s Spine Segment from | |
| November 2011 through November 2012. The Spine President is no longer employed by | |
| Orthofix. | |
| The Spine Sales VP served as the Vice President of Global Sales and Development for | |
| the international portion of Orthofix’s Spine Segment from March 2011 until May 2013. The | |
| Spine Sales VP is no longer employed by Orthofix. | |
| The Corporate CFO served as Orthofix’s Chief Financial Officer from March 2011 | |
| through November 2012. In November 2012, the Corporate CFO became the President of | |
| Orthofix’s Spine Segment until he left Orthofix in July 2013. In the Order, we use the term New | |
| Spine President/Prior Corporate CFO to describe this person’s conduct from November 2012 | |
| and beyond. | |
| FACTS | |
| A. Orthofix’s Business and Structure | |
| 1. Orthofix’s business was primarily divided into two Global Business Segments during the | |
| relevant period – Spine and Orthopedics. During the relevant period, Spine was | |
| Orthofix’s largest segment and contributed two-thirds of the company’s overall revenues. | |
| 2. Spine had several operating divisions during the relevant period. For example, Orthofix | |
| Spinal Implants (“OSI”) was responsible for international sales of spinal implants and | |
| related instruments. | |
| 3. During the relevant period, the Spine CFO was responsible for the accounting and | |
| financial functions of Spine, including preparing its operating results (which were | |
| included in Orthofix’s public filings with the Commission). | |
| 4. The Spine CFO reported directly to Spine’s President, a salesperson, during the relevant | |
| period. The Spine President was in charge of Spine’s sales and overall management. | |
| The Spine President had several sales persons who worked under him, including an | |
| individual who served as Spine’s Vice President of Global Sales and Development | |
| (“Spine Sales VP”). | |
| 4 | |
| 5. In essence, the Spine Sales VP was the relationship manager for a number of | |
| relationships that OSI had with certain international distributors. The Spine Sales VP had | |
| a sales team of approximately four employees who reported to him and had day-to-day | |
| responsibility for certain distributor relationships. | |
| 6. While the Spine CFO reported directly to the Spine President during the relevant period, | |
| the Spine CFO also had dotted line reporting responsibility to Orthofix’s Corporate CFO | |
| (hereinafter “Corporate CFO”). The Corporate CFO was responsible for the preparation | |
| of Orthofix’s public filings, including its consolidated financial results. | |
| 7. Spine sold various products including spinal and cervical implants and related | |
| instruments. The instruments and implants were interconnected as implants could not be | |
| used in patients without functioning instrument sets. | |
| 8. Spine sold the above products through two primary methods: (i) sales of its products to | |
| U.S. and international distributors who then sold the products to hospitals and physicians | |
| and (ii) sales of its products directly to hospitals and physicians in the U.S. | |
| B. Orthofix’s Revenue Recognition Policies and Practices and Distributor Business Practices | |
| a. Revenue Recognition Policies and Practices | |
| 9. ASC 605-10-25-1 provides that revenue may be recognized only when it is both realized | |
| or realizable and earned. Consistent with the authoritative literature, Orthofix’s financial | |
| statements disclosed four criteria as its revenue recognition policy. | |
| 10. The four criteria are: (i) persuasive evidence of an arrangement exists; (ii) delivery has | |
| occurred or services have been rendered; (iii) the seller’s price to the buyer is fixed and | |
| determinable; and (iv) collectability is reasonably assured. | |
| 11. Other than the four criteria disclosed in its filings, Orthofix did not have any other | |
| revenue recognition policies during the relevant period and failed to adequately document | |
| how it satisfied the four criteria with respect to the sales transactions that were recognized | |
| as revenue. Moreover, Orthofix could not and did not reasonably estimate the revenue | |
| recognition impact of the amount of future returns when extra-contractual agreements | |
| included rights of return. | |
| 12. With limited exceptions, Orthofix recognized revenue during the relevant period based on | |
| the “sell-in” method, which provides for revenue recognition upon shipment of products | |
| to the distributor. | |
| b. Distributor Business Practices During the Relevant Period | |
| 13. Orthofix entered into written agreements with distributors of its product. These | |
| distributor agreements provided, among other things, standard payment terms for | |
| purchase of products. These standard payment terms ranged typically from 90 to 180 | |
| days. | |
| 5 | |
| 14. During the relevant period, Spine had an unwritten policy requiring that modifications to | |
| the terms in existing distributor agreements had to be approved by the Spine CFO. The | |
| Spine CFO’s approval authority in this regard extended to all aspects of distributor | |
| agreement terms, including pricing, commissions, discounts, extensions of payment | |
| terms, payment plans, returns, and exchanges. The Spine CFO was the only person | |
| within OSI who had any type of revenue recognition training. | |
| 15. Moreover, Orthofix did not have any policies and procedures requiring the analysis | |
| and/or documentation of the impact, from a revenue recognition perspective, of | |
| modifications to the standard contractual terms contained in distributor agreements. | |
| C. Orthofix Aggressively Set Internal Sales Targets and Imposed Pressure to Meet those | |
| Targets | |
| 16. During the relevant period, Orthofix had a culture of aggressively setting internal sales | |
| targets and imposing pressure upon its sales personnel to meet those targets. | |
| 17. Spine generally set sales targets in the following manner. Towards the end of a fiscal | |
| year, the Spine sales leaders prepared sales forecasts (by month, quarter, and for the year) | |
| for the upcoming fiscal year and sent those forecasts to the Spine President and Spine | |
| CFO. The Spine President and Spine CFO then reviewed and approved the forecasts | |
| before adding the costs components to prepare a budget which included the revenue | |
| targets. | |
| 18. The budget was then sent to the then-Company CEO who approved the budget or rejected | |
| it. If the budget was rejected, it was revised for review and resubmitted to the Company | |
| CEO for approval. | |
| 19. On August 28, 2012 – and reflecting the pressure imposed to meet revenue targets – the | |
| Spine Sales VP sent the following email to his sales team with the subject line | |
| “September Gut:” | |
| I need your gut feeling on the revenue we can generate in September. We need $2 | |
| million in addition to what is on the portal . . .based on the feedback I have received I | |
| have gotten so far, we are off about $1.5 million. I know what people say they need, | |
| but as you know this is important. We need to ask everyone to purchase just a bit | |
| more . . .if I have to walk into [the Spine President’s] office and tell him we are short | |
| again, that is going to be a major problem. | |
| 20. After receiving the above email, one of the sales persons who reported to the Spine Sales | |
| VP emailed a colleague separately and wrote: | |
| I was just speaking with [the Spine Sales VP] and had finance listened to us last year | |
| we wouldn’t be in this mess. We all predicted our markets could not sustain this | |
| growth but they got greedy. Found this budget brutal because here we are for another | |
| year just estimating the dollars. | |
| 6 | |
| D. Orthofix Improperly Recognized Revenue on Several Transactions with Brazilian | |
| Distributor | |
| a. Orthofix Improperly Recognized $5 Million in Revenue in FY 2011 by Selling | |
| Implants without Instrument Sets | |
| 21. OSI had several international distributors during the relevant period, but its largest | |
| distributor of product was located in Brazil (hereinafter “the Brazilian Distributor”). In | |
| fact, for eight of the nine quarters from Q1 2011 to Q1 2013, the Brazilian Distributor | |
| was the Company’s second largest customer on a revenue per quarter basis. | |
| 22. Entering 2011, Orthofix had a receivable of approximately $5 million from the Brazilian | |
| Distributor from prior sales. After discussions with the Spine President and Spine Sales | |
| VP, the Brazilian Distributor forecasted that it would purchase approximately $8.5 | |
| million of Orthofix implants and instruments in FY 2011. | |
| 23. Prior to this time, Orthofix had sold implants along with used instrument sets rather than | |
| new ones to the Brazilian Distributor. As discussed above, implants and instruments | |
| were interconnected because the implants could not be used in patients without related | |
| instrument sets. | |
| 24. At this time, however, the Brazilian Distributor could no longer purchase previously used | |
| instrument sets because ANVISA (the Brazilian equivalent of the U.S. Food and Drug | |
| Administration) imposed new regulations prohibiting the importation of used instrument | |
| sets. | |
| 25. Orthofix did not have the new instrument sets (105 in total) available to be shipped along | |
| with the implants it shipped to the Brazilian Distributor. Rather than waiting until the | |
| new instrument sets were available, Orthofix – in FY 2011 – shipped approximately $5 | |
| million in implants to the Brazilian Distributor despite the fact that these implants could | |
| not be used in patients without the new instrument sets. | |
| 26. Orthofix recognized the approximately $5 million revenue upon shipment of the above | |
| implants. Orthofix’s recognition of revenue in this regard was improper as delivery of | |
| the interconnected product – the instruments – had not yet occurred. Orthofix knew that | |
| the implants could not be used in patients without the instruments. As such, payment | |
| timing and terms were contingent upon the instrument sets being made available and | |
| therefore, revenue recognition was inconsistent with Orthofix’s accounting policy | |
| because it did not meet the fixed or determinable criteria or the collectability criteria. | |
| 27. This improper recognition of revenue caused Orthofix’s financial statements to be | |
| materially misstated in its Forms 10-Q for the second and third quarters of FY 2011 and | |
| its year-end Form 10-K for FY 2011 and corresponding earnings releases. | |
| 28. By the beginning of FY 2012, virtually none of the 105 instrument sets had been shipped | |
| to the Brazilian Distributor. Thus, the Brazilian Distributor refused to pay for the | |
| implants because those implants that Orthofix had previously shipped to the Brazilian | |
| 7 | |
| Distributor could not be used without the instrument sets. As a result, the Brazilian | |
| Distributor’s amounts payable to Orthofix increased from approximately $5 million at the | |
| beginning of FY 2011 to approximately $11 million at the beginning of FY 2012. | |
| 29. In March 2012, the Spine President and Spine Sales VP had discussions with the | |
| Brazilian Distributor concerning a payment plan to address the increasing amounts | |
| payable. The Brazilian Distributor agreed to pay approximately $4.2 million of the | |
| amounts payable by the end of FY 2012 but only if all the remaining 105 instrument sets | |
| were delivered by the end of April 2012. | |
| 30. The Spine President and Spine Sales VP agreed to this payment plan proposal without | |
| approval from the Spine CFO. | |
| 31. By April 30, 2012, Orthofix had only shipped 40 of the 105 instrument sets. | |
| Accordingly, in June 2012, the Brazilian Distributor informed the Spine Sales VP and | |
| Spine President that it would only pay $1.6 million of its amounts payable in December | |
| 2012 and $2.6 million in February 2013. | |
| 32. The Spine President and Spine Sales VP agreed to this payment plan proposal without | |
| approval from the Spine CFO. More broadly – throughout the relevant period – Orthofix | |
| did not establish and maintain procedures to reasonably ensure proper communication to | |
| the Company’s finance and accounting departments of deviations from contractually | |
| established terms, which included written or unwritten agreements made with Company | |
| distributors. | |
| b. Orthofix Improperly Recognized Even More Revenue with the Brazilian | |
| Distributor in Summer 2012 | |
| 33. In late May 2012, the Spine President discussed a product launch plan with the Brazilian | |
| Distributor to purchase approximately $2.5 million of a new Orthofix implant product | |
| called Firebird. This product, however, had not yet been approved by ANVISA and, | |
| therefore, could not be shipped into Brazil until such approval was obtained. | |
| 34. The Brazilian Distributor agreed to place the order on the following conditions: (i) one | |
| year to pay for the implants contingent on ANVISA approval; (ii) 210 days to pay on all | |
| subsequent product orders; and (iii) all corresponding instrument sets needed to be | |
| available once ANVISA approved the implants. Neither Orthofix nor the Brazilian | |
| Distributor knew when ANVISA would grant approval. | |
| 35. Moreover – despite the fact that the Brazilian Distributor was provided 210 days to pay | |
| on any subsequent purchase orders – the new payment terms were not reflected in any | |
| revised or amended distributor agreement with the Brazilian Distributor. | |
| 36. The Spine CFO learned of this transaction a few weeks after the product had been | |
| shipped but before the company filed its third quarter FY 2012 financial results. In | |
| particular – on July 24, 2012 – the Spine Sales VP forwarded the Spine CFO an email | |
| 8 | |
| describing the transaction along with a series of emails containing prior discussions | |
| between him and the Brazilian Distributor’s President. | |
| 37. The Spine CFO replied to the Spine Sales VP and the Spine President – “[Spine Sales | |
| VP], can you please address how we ended up with a full year to pay for the June order. I | |
| have a hard time managing that with a lot of pressure to reduce our ballooning [Days | |
| Sales Outstanding].” The Spine Sales VP replied, “we accepted this due to the need for | |
| that size of an order.” | |
| 38. Despite the contingent nature of the sale and the Spine CFO’s own concerns about how | |
| this transaction would impact the company’s Days Sales Outstanding, the over $2 million | |
| in revenue from this transaction was recognized immediately upon shipping the implants | |
| to the Brazilian Distributor’s U.S. based subsidiary located in Atlanta, Georgia. | |
| 39. Orthofix’s recognition of revenue in this regard was improper because the Brazilian | |
| Distributor’s obligation to pay, and the payment terms themselves, were contingent upon | |
| ANVISA approval and, therefore, revenue recognition was inconsistent with Orthofix’s | |
| accounting policy because it did not meet the fixed or determinable criteria or the | |
| collectability criteria. | |
| c. Corporate CFO Became Aware of Issues with Implant Without Instruments | |
| Transactions | |
| 40. The Corporate CFO – soon after beginning in that role in early 2011 – implemented a | |
| general unwritten bad debt policy applicable to both Spine and Orthopedics. The policy | |
| required that any accounts receivable that had been outstanding at least 360 days from the | |
| invoice date of a shipment had to be fully reserved as bad debt. The Corporate CFO, | |
| along with the Corporate Controller and Segment CFOs, were responsible for the | |
| calculation of the bad debt reserve. | |
| 41. On August 1, 2012 – two days after Orthofix had filed its Form 10-Q for the second | |
| quarter of FY 2012 and as part of the process for handling Orthofix’s bad debt calculation | |
| – the Corporate Controller emailed the Spine CFO an aging schedule identifying that as | |
| of June 30, 2012 approximately $4 million of amounts owed to OSI was over one year | |
| old.2 | |
| 42. The aging schedule contained in this email, however, demonstrated that the allowance for | |
| doubtful accounts as of the second quarter of FY 2012 was only $1.6 million (or 40% of | |
| accounts receivable over 360 days old). The Corporate Controller then wrote “what | |
| doesn’t make sense is that our policy is to reserve all amounts in the [over one year old | |
| bucket].” | |
| 2 Orthofix used the term “360+ day bucket” to denote amounts due over one year old. | |
| 9 | |
| 43. The Corporate Controller then forwarded the email to the Corporate CFO and wrote the | |
| following: | |
| I spoke with [the Spine CFO] on this. The rationale for not reserving all of the | |
| 360+ bucket for [Spine] is that technically the receivable balance from [the | |
| Brazilian Distributor] is not >360 days old since they have extended terms in their | |
| contract. The aging schedule is based on days past the invoice date for all | |
| [accounts receivable]. To further exacerbate the situation, [the Brazilian | |
| Distributor] could not sell the Implants inventory that we sold to them in 2011 | |
| since we were delayed in sending them the instrument sets that they needed to sell | |
| the Implants). This one-year delay was caused by [ANVISA] who required us to | |
| send new instruments (as opposed to our original plan to move used instruments). | |
| 44. The Corporate Controller further noted in the email that – based on discussions he had | |
| with the Spine CFO – the Brazilian Distributor planned to make a $4 million payment in | |
| December 2012 that would significantly reduce the 360+ day bucket in the year-end | |
| aging presentation. | |
| 45. Unbeknownst to the Corporate Controller and the Spine CFO, however – and as another | |
| example of Orthofix’s inadequate internal accounting controls surrounding distributor | |
| revenue recognition – the Brazilian Distributor had already informed the Spine President | |
| and Spine Sales VP that it would only pay $1.6 million in December 2012 and another | |
| $2.6 million in February 2013 because the 105 instrument sets had not been delivered in | |
| full in April 2012. | |
| 46. Through this email, the Corporate CFO was on notice that Orthofix had a significant | |
| outstanding receivable associated with implants for which there had been an at least one | |
| year delay in sending the corresponding instrument sets. | |
| 47. The Corporate CFO, however, did not take steps to investigate the circumstances of the | |
| original transaction and to determine whether the revenue associated with the original | |
| transaction had been properly recognized. As noted earlier, Orthofix improperly | |
| recognized $5 million of revenue because the implants could not be used in patients | |
| without the instruments. As such, payment timing and terms were contingent upon the | |
| instrument sets being made available and, therefore, revenue recognition was inconsistent | |
| with Orthofix’s accounting because it did not meet the fixed or determinable criteria or | |
| the collectability criteria. | |
| 48. Orthofix had inadequate internal accounting controls to evaluate the impact of these facts | |
| on the revenue that was previously recognized on this transaction. In particular, Orthofix | |
| did not establish and maintain procedures to reasonably ensure an assessment by the | |
| Company’s finance and accounting department of deviations from contractually | |
| established terms. | |
| d. Orthofix Improperly Recognized Even More Revenue with the Brazilian | |
| Distributor in Fall 2012 | |
| 10 | |
| 49. In the fall of 2012, Orthofix improperly recognized even more revenue with the Brazilian | |
| Distributor. By the fall of 2012, the Spine President had left the company and was | |
| replaced in that role by the Corporate CFO (hereinafter “New Spine President/Prior | |
| Corporate CFO”).3 | |
| 50. Beginning in September 2012, the Spine Sales VP solicited the Brazilian Distributor to | |
| purchase approximately $1.5 million of Orthofix implants that had not yet been approved | |
| by ANVISA. Thus – as with the summer 2012 sales transaction with the Brazilian | |
| Distributor – this product could not be shipped into Brazil until that approval occurred. | |
| 51. The Brazilian Distributor indicated that it would agree to the purchase but only under the | |
| following two conditions: (i) the ability to renegotiate the payment terms if ANVISA | |
| approval did not occur by the end of 2012 (just three months away) and (ii) one year to | |
| pay for the product. Neither Orthofix nor the Brazilian Distributor knew when ANVISA | |
| would grant approval. | |
| 52. Despite the conditions noted above, Orthofix recognized the revenue from this | |
| transaction immediately upon shipping the implants to the Brazilian Distributor’s | |
| warehouse located in the United States. In particular, Orthofix’s recognition of revenue | |
| in this regard was improper because the Brazilian Distributor’s obligation to pay, and the | |
| payment terms themselves, were contingent upon ANVISA approval and, therefore, | |
| revenue recognition was inconsistent with Orthofix’s accounting policy because it did not | |
| meet the fixed or determinable criteria or the collectability criteria. | |
| 53. This improper recognition of revenue – in combination with the improper recognition of | |
| revenue for other transactions in FY 2012 described previously and later – caused | |
| Orthofix’s financial results in its FY 2012 Form 10-K (and corresponding earnings | |
| release) to be materially misstated. | |
| e. The Brazilian Distributor’s President Described Transactions to Spine CFO and | |
| Spine Sales VP | |
| 54. As discussed previously, in March 2012, the Spine President and Spine Sales VP | |
| discussed a payment plan proposal such that the Brazilian Distributor would pay | |
| approximately $4.2 million of its amounts owed by the end of 2012. The Brazilian | |
| Distributor responded that it would only agree to this payment if all of the 105 instrument | |
| sets were delivered by the end of April 2012. When these instrument sets were not | |
| delivered by April 2012, the Brazilian Distributor informed the Spine President and Spine | |
| Sales VP in June 2012 that it would only pay $1.6 million in December 2012 and $2.6 | |
| million in February 2013. | |
| 3 The then-CFO of Orthofix’s Orthopedics Segment replaced the New Spine President/Prior Corporate CFO | |
| as the Corporate CFO. | |
| 11 | |
| 55. On December 1, 2012, the Spine Sales VP emailed the Brazilian Distributor’s President | |
| and wrote “I believe you have been speaking with [the Spine CFO] about the end of the | |
| year payment of $4 million. They are all extremely anxious about this. This has to | |
| happen as agreed.” | |
| 56. The Brazilian Distributor’s President replied “No [the Spine CFO] did not communicate | |
| with me, certainly because it is quite clear this was agreed with [the Spine President]. | |
| We will pay $1.6 million in December.” | |
| 57. The Spine Sales VP forwarded this email to the Spine CFO, writing “this is a disaster,” | |
| despite the fact that the Spine Sales VP had been informed in June 2012 that the Brazilian | |
| Distributor would only pay $1.6 million in December 2012. The Spine CFO then | |
| forwarded the above email to the New Spine President/Prior Corporate CFO and wrote: | |
| [The Brazilian Distributor’s President] says below they made a payment agreement | |
| with [the Spine President] . . .I have no idea what may have been promised. I do | |
| know that I fought pricing and terms concessions, but those were ultimately given at | |
| some point despite my denials. This was commonplace. I was told that I was the | |
| decision maker on pricing and terms and then secretly overridden. [The Spine Sales | |
| VP] did it all of the time – don’t know how much [the Spine President] was involved. | |
| 58. On December 7, 2012, the Brazilian Distributor’s President travelled to the U.S. to meet | |
| with the Spine CFO and Spine Sales VP. At that meeting, the Brazilian Distributor’s | |
| President provided a Power Point presentation to the Spine CFO and Spine Sales VP with | |
| a detailed chronology of events on each of the sales transactions described previously, | |
| including the implant-without-instruments transactions, the June and September 2012 | |
| transactions, and the payment plan related issues. | |
| 59. The Spine CFO subsequently forwarded the Power Point presentation to the New Spine | |
| President/Prior Corporate CFO. The Spine CFO did not forward this Power Point | |
| presentation to the company’s then Corporate CFO and did not reassess the revenue that | |
| the company had previously recognized and disclosed in its financial statements. | |
| 60. The New Spine President/Prior Corporate CFO failed to confirm that this Power Point | |
| presentation had been brought to the attention of the then Corporate CFO and did not | |
| separately confirm that the transactions outlined in the Power Point presentation had been | |
| separately discussed with the Corporate CFO. Moreover, the New Spine President/Prior | |
| Corporate CFO failed to evaluate the impact that the information contained in the Power | |
| Point had on the revenue that the company had previously recognized and disclosed in its | |
| financial statements when he served as the company’s Corporate CFO. | |
| 61. Ultimately, Orthofix filed its FY 2012 Form 10-K in March 2013 and took no steps to | |
| correct the revenue that it had previously improperly recognized on the implants-without | |
| instruments, Firebird, and September 2012 transactions with the Brazilian Distributor. | |
| Moreover, Orthofix did not adequately assess the collectability of the significant | |
| receivables it had with the Brazilian Distributor. | |
| 12 | |
| 62. As a result of this and other errors described below, Orthofix materially misstated its | |
| financial results in its FY 2012 Form 10-K and corresponding earnings release. | |
| E. Orthofix Improperly Recognized Revenue with Other Spine International Distributors | |
| a. Introduction | |
| 63. In addition to the Brazilian Distributor, OSI had relationships with other international | |
| distributors including in Italy, Spain, and Mexico. In total, these four international | |
| distributors accounted for over 70% of OSI’s revenue and almost 4% of Orthofix’s | |
| consolidated revenue in FY 2011 and 2012. | |
| 64. Orthofix improperly recognized revenue with each of these distributors and did not have | |
| adequate internal accounting controls to provide reasonable assurance that transactions | |
| with these distributors were recorded as necessary to permit the preparation of financial | |
| statements in conformity with GAAP. | |
| b. Italy | |
| 65. On October 22, 2011, the Spine President emailed the Company CEO, Corporate CFO, | |
| Spine CFO, and Spine Sales VP concerning the need for OSI to meet its fourth quarter | |
| fiscal year 2011 forecast of $6 million in revenue. The Spine President wrote “if we fail | |
| at this endeavor then the company will be at risk and next year will be Hell on Earth for | |
| all of us.” | |
| 66. In early December 2011 – in an attempt to meet Spine’s internal sales targets for the | |
| fourth quarter of FY 2011 – the Spine Sales VP emailed the Italian Distributor and | |
| solicited it to make a $400,000 order. The Italian Distributor’s President responded that | |
| it could make the order if they had extended payment terms of 180 days and the ability | |
| “in case of cash difficulties” to extend those payment terms. Moreover, the Italian | |
| Distributor’s President noted that “it is a very bad moment for Italy.” | |
| 67. The Spine CFO was copied on these email exchanges and, despite the specifically | |
| identified financial difficulties in Italy, Orthofix recorded the revenue upon shipment of | |
| the products. This revenue recognition upon shipment was improper because payment | |
| terms were contingent upon timing of the Italian Distributor’s sell-through and payment | |
| receipt of the products and, therefore, revenue recognition was inconsistent with | |
| Orthofix’s accounting policy because it did not meet the fixed or determinable criteria or | |
| the collectability criteria. | |
| c. Spain | |
| 68. In early December 2011, the Spine Sales VP, by email, solicited the Spanish Distributor | |
| to make a $300,000 order. The Spanish Distributor noted the difficult conditions in the | |
| Spanish economy at the time. The Spine Sales VP responded that “based on the expected | |
| challenges in Europe due to the instability of the financial institutions,” he could offer | |
| extended payment terms of 180 days for instruments and 150 days for implants. | |
| 13 | |
| 69. In late December 2011, the Spine Sales VP forwarded this email exchange to the Spine | |
| CFO for his approval of the extended payment terms. The Spine CFO provided his | |
| approval. Orthofix recognized the revenue from this transaction upon shipment of the | |
| products and this was improper because it did not meet the fixed or determinable criteria. | |
| 70. In July 2012, the Spine Sales VP, without getting the approval of the Spine CFO, | |
| solicited the Spanish Distributor to place an $810,000 order in which he offered the | |
| Distributor certain concessions, which he characterized as the “deal of the century.” The | |
| concessions included extended payment terms on the order and the right to return | |
| $250,000 of excess distributor inventory that resulted from the order. Orthofix’s | |
| recognition of revenue from this transaction upon shipment of the products was improper | |
| because payment terms and timing were contingent upon certain extra-contractual | |
| concessions and, therefore, revenue recognition was inconsistent with Orthofix’s | |
| accounting policy because it did not meet the fixed or determinable criteria or the | |
| collectability criteria. | |
| d. Mexico | |
| 71. In September 2012, the Spine Sales VP, without getting the approval of the Spine CFO, | |
| solicited the Mexican Distributor to place a $300,000 order in which he offered the | |
| Distributor a number of concessions. The concessions included extended payment terms | |
| on the order, and expansion of sales territory and reduction in sales quotas for the next | |
| year. Orthofix’s recognition of revenue from this transaction upon shipment of the | |
| products was improper because payment terms and timing were contingent upon certain | |
| extra contractual concessions and, therefore, revenue recognition was inconsistent with | |
| Orthofix’s accounting policy because it did not meet the fixed or determinable criteria or | |
| the collectability criteria. | |
| F. Orthofix Improperly Accounted for Spinal Stimulation Product Transactions | |
| 72. Orthofix’s revenue recognition issues were not just limited to transactions with certain of | |
| its international distributors for spinal products. Orthofix also improperly accounted for | |
| certain domestic distributor transactions in Spine involving spine stimulation products. | |
| 73. Beginning in the first quarter of FY 2012, the Spine President began exploring | |
| opportunities to generate more revenue in the domestic spine market by selling spine | |
| stimulation products to wholesale distributors. Prior to this time, Orthofix sold these | |
| products directly to patients, doctors and hospitals. The Spine President began exploring | |
| selling these products directly to wholesale distributors who would then resell them to | |
| doctors and hospitals. | |
| 74. At this time, the wholesale market for these products was dominated by an Orthofix | |
| competitor. To draw market share away from this competitor, the Spine President and | |
| Spine CFO determined that they would need to sell Orthofix spinal stimulation products | |
| at deeply discounted prices. | |
| 14 | |
| 75. Accordingly, the Spine President and Spine CFO decided they would offer the | |
| wholesalers products at deeply discounted prices-per-unit. Moreover, Orthofix paid a | |
| referral fee to the wholesaler that was termed as a “commission.” | |
| 76. For example, if Orthofix agreed to sell 100 units for $1,500 per unit, or $150,000, | |
| Orthofix also agreed to pay the wholesaler a commission of 25%, or $37,500, which | |
| essentially reduced the amount being paid for the product to $112,500 ($150,000 less | |
| $37,500). | |
| 77. Orthofix improperly treated these commissions as expenses rather than as reductions to | |
| revenue. Orthofix’s accounting treatment was improper because where the vendor does | |
| not receive an identifiable benefit for the commissions, sales discounts such as these are | |
| presumed to be a reduction in the seller’s price pursuant to ASC 605-50-45-2. Thus, | |
| these commissions should have been treated as further price discounts and as a reduction | |
| in revenue. | |
| 78. Due to this improper accounting, Orthofix overstated its revenue by approximately $1.7 | |
| million in FY 2012, with the overwhelming majority of this amount (approximately $1.4 | |
| million) being overstated in the third quarter of FY 2012. | |
| 79. Moreover, Orthofix improperly recognized revenue upon shipment on two of the spinal | |
| stimulation transactions in which the purchaser was granted a right to exchange the | |
| products for cervical stimulation products. | |
| 80. In particular – because Orthofix could not and did not reasonably estimate the revenue | |
| recognition impact of the amount of future returns – Orthofix was precluded from | |
| recognizing revenue upon shipment in the above transactions pursuant to ASC 605-15- | |
| 25-1(f). | |
| 81. As a result, Orthofix overstated its revenue by over $650,000 in FY 2012, with all of this | |
| revenue being improperly recognized in the third quarter of FY 2012. | |
| G. Orthofix Engaged in Improper Accounting at its Orthopedics Brazilian Subsidiary | |
| 82. As noted earlier, Orthofix had two primary business segments during the relevant period | |
| – Spine and Orthopedics. Within Orthopedics, Orthofix had a Brazilian subsidiary | |
| known as Orthofix do Brazil. During the relevant period, the Orthofix do Brazil | |
| subsidiary had inadequate internal accounting controls surrounding revenue recognition | |
| and, as a result, improperly recognized revenue associated with certain distributor | |
| transactions upon shipment. | |
| 83. In particular, Orthofix do Brazil used side agreements that included extended payment | |
| terms and other concessions, and therefore, did not meet the revenue recognition | |
| requirements upon shipment of the product. | |
| 84. Moreover, Orthofix do Brazil improperly recognized revenue upon shipment in at least | |
| FY 2011 and FY 2012 as a result of providing distributors with rights to both exchange | |
| and return products. | |
| 15 | |
| H. Orthofix Improperly Calculated its Excess and Obsolete Reserve for Certain of Its | |
| Inventory | |
| 85. During the relevant period, Orthofix calculated an excess and obsolete (E&O) reserve for | |
| its inventory. In essence, the E&O calculation serves as an estimated reserve against | |
| inventory based on – among other things – assumptions related to the marketability or | |
| saleability of inventory on hand. | |
| 86. During the relevant period, Orthofix improperly calculated or accounted for its E&O | |
| reserve in two respects. First – in the third quarter of FY 2011 – Orthofix launched a new | |
| product called FORZA. Orthofix experienced issues with FORZA’s launch and therefore | |
| took an E&O reserve totaling approximately $1.2 million in the second quarter of fiscal | |
| year 2012. | |
| 87. In the fourth quarter of fiscal year 2012, a new E&O calculation policy was implemented | |
| at Spine to conform the E&O calculation performed at another Orthofix segment since at | |
| least 2007. | |
| 88. The updated E&O policy, among other things, provided that an E&O reserve would not | |
| be taken in the first four years of a product’s launch. Applying that policy, in the fourth | |
| quarter of FY 2012 the Spine CFO reversed the reserve originally booked in the second | |
| quarter of FY 2012 (which resulted in a $1.2 million gross margin increase in the fourth | |
| quarter of FY 2012). | |
| 89. On restatement, however, Orthofix concluded that the FORZA E&O reserve should not | |
| have been reversed due to the fact that issues with FORZA’s launch had indeed impacted | |
| demand. | |
| 90. Second, in connection with the company’s restatement process and based on a previously | |
| known design deficiency in the company’s controls over the computation and recording | |
| of its E&O reserve, Orthofix reviewed the broader methodology it used to compute and | |
| record its inventory reserve. Based on this review, Orthofix determined that it had | |
| improperly made reductions to previously recorded reserves based on changes in | |
| forecasted demand in contravention of ASC 330.4 | |
| 91. As a result of its improper reserve accounting for this broader issue and the FORZA issue | |
| noted above, Orthofix understated its E&O reserve by $3.4 million and $5.6 million in | |
| FY 2011 and 2012, respectively. | |
| I. Orthofix’s Restatement | |
| 4 ASC Topic 330, Inventory (specifically ASC 330-10-35-14) states that a write-down below cost at the | |
| close of a fiscal year creates a new cost basis. | |
| 16 | |
| 92. In late March 2014, Orthofix restated its financial statements for the first quarter of fiscal | |
| year 2013, all quarterly and annual periods in fiscal years 2012 and 2011, and the annual | |
| period for fiscal year 2010. | |
| 93. As a result of certain improper distributor revenue recognition practices, Orthofix | |
| announced that it had overstated – for example – fiscal year 2011 net sales by | |
| approximately 6% and operating income by over 430%. Moreover, in the restatement, | |
| Orthofix acknowledged certain material weaknesses in its internal control over financial | |
| reporting. | |
| VIOLATIONS | |
| 94. Securities Act Section 17(a)(2) prohibits any person from obtaining money or property in | |
| the offer or sale of securities by means of any untrue statement of a material fact or any | |
| omission to state a material fact necessary in order to make the statements made, in light | |
| of the circumstances under which they were made, not misleading. | |
| 95. Securities Act Section 17(a)(3) prohibits any person from engaging in any transaction, | |
| practice, or course of business which operates or would operate as a fraud or deceit upon | |
| the purchaser in the offer or sale of securities. | |
| 96. Section 13(a) of the Exchange Act requires issuers to file such periodic and other reports | |
| as the Commission may prescribe and in conformity with such rules as the Commission | |
| may promulgate. Exchange Act Rules 13a-1, 13a-11, and 13a-13 require the filing of | |
| annual, current, and quarterly reports, respectively. In addition to the information | |
| expressly required to be included in such reports, Rule 12b-20 of the Exchange Act | |
| requires issuers to add such further material information, if any, as may be necessary to | |
| make the required statements, in the light of the circumstances under which they are | |
| made not misleading. “The reporting provisions of the Exchange Act are clear and | |
| unequivocal, and they are satisfied only by the filing of complete, accurate, and timely | |
| reports.” SEC v. Savoy Industries, 587 F.2d 1149, 1165 (D.C. Cir. 1978) (citing SEC v. | |
| IMC Int’1, Inc., 384 F. Supp. 889, 893 (N.D. Tex. 1974)). A violation of the reporting | |
| provisions is established if a report is shown to contain materially false or misleading | |
| information. SEC v. Kalvex, Inc., 425 F. Supp. 310, 316 (S.D.N.Y. 1975). | |
| 97. Section 13(b)(2)(A) of the Exchange Act requires issuers to “make and keep books, | |
| records, and accounts, which, in reasonable detail, accurately and fairly reflect the | |
| transactions and dispositions of the assets of the issuer.” Section 13(b)(2)(B) of the | |
| Exchange Act requires issuers to devise and maintain a system of internal accounting | |
| controls sufficient to provide reasonable assurances that transactions are recorded as | |
| necessary to permit the preparation of financial statements in conformity with generally | |
| accepted accounting principles. | |
| 98. As a result of the conduct described above, Orthofix violated Securities Act Sections | |
| 17(a)(2) and 17(a)(3) and Exchange Act Sections 13(a), 13(b)(2)(A), and 13(b)(2)(B) and | |
| Rules 12b-20, 13a-1, 13a-11, and 13a-13. | |
| 17 | |
| COOPERATION AND REMEDIAL ACTION | |
| In determining to accept Respondent’s Offer, the Commission considered remedial acts | |
| undertaken by Orthofix, including its enhancement of internal controls, the restructuring and | |
| strengthening of the Company’s accounting and finance group (which includes retention of | |
| additional accounting personnel), and Orthofix’s cooperation with the staff’s investigation. | |
| IV. | |
| In view of the foregoing, the Commission deems it appropriate to impose the sanctions | |
| agreed to in Respondent’s Offer. | |
| Accordingly, it is hereby ORDERED that: | |
| A. Pursuant to Section 8A of the Securities Act and Section 21C of the Exchange | |
| Act, Respondent cease and desist from committing or causing any violations and any future | |
| violations of Securities Act Section 17(a)(2) and 17(a)(3), and Exchange Act Sections 13(a), | |
| 13(b)(2)(A), 13(b)(2)(B) and Rules 12b-20, 13a-1, 13a-11, and 13a-13 thereunder. | |
| B. Respondent shall, within 30 days of the entry of this Order, pay a civil money | |
| penalty in the amount of $8,250,000 to the Securities and Exchange Commission. If timely | |
| payment is not made, additional interest shall accrue pursuant to 31 U.S.C. § 3717. Payment | |
| must be made in one of the following three ways: | |
| (1) Respondent may transmit payment electronically to the Commission, which | |
| will provide detailed ACH transfer/Fedwire instructions upon request | |
| 5 | |
| ; | |
| (2) Respondent may make direct payment from a bank account via Pay.gov | |
| through the SEC website at http://www.sec.gov/about/offices/ofin.htm; or | |
| (3) Respondent may pay by certified check, bank cashier’s check, or United | |
| States postal money order, made payable to the Securities and Exchange | |
| Commission and hand-delivered or mailed to: | |
| Enterprise Services Center | |
| Accounts Receivable Branch | |
| HQ Bldg., Room 181, AMZ-341 | |
| 6500 South MacArthur Boulevard | |
| Oklahoma City, OK 73169 | |
| Payments by check or money order must be accompanied by a cover letter identifying | |
| Orthofix as a Respondent in these proceedings, and the file number of these proceedings; a copy | |
| 5 | |
| The minimum threshold for transmission of payment electronically is $1,000,000. For amounts below the | |
| threshold, respondents must make payments pursuant to option (2) or (3) above. | |
| 18 | |
| of the cover letter and check or money order must be sent to Antonia Chion, Division of | |
| Enforcement, Securities and Exchange Commission, 100 F Street, NE, Washington, DC 20549- | |
| 5720. | |
| C. Pursuant to Section 308(a) of the Sarbanes-Oxley Act of 2002, as amended, a Fair | |
| Fund is created for the penalties referenced in paragraph IV.B above. This Fair Fund may receive | |
| the funds from and/or be combined with fair funds established for civil penalties paid by other | |
| respondents for conduct arising in relation to the violative conduct at issue in this Orthofix | |
| proceeding, in order for the combined fair funds to be distributed to harmed investors affected by | |
| the violative conduct. Amounts ordered to be paid as civil money penalties pursuant to this Order | |
| shall be treated as penalties paid to the government for all purposes, including all tax purposes. | |
| To preserve the deterrent effect of the civil penalty, Respondent agrees that in any Related | |
| Investor Action, it shall not argue that it is entitled to, nor shall it benefit by, offset or reduction | |
| of any award of compensatory damages by the amount of any part of Respondent’s payment of a | |
| civil penalty in this action (“Penalty Offset”). If the court in any Related Investor Action grants | |
| such a Penalty Offset, Respondent agrees that it shall, within 30 days after entry of a final order | |
| granting the Penalty Offset, notify the Commission's counsel in this action and pay the amount of | |
| the Penalty Offset to the Securities and Exchange Commission. Such a payment shall not be | |
| deemed an additional civil penalty and shall not be deemed to change the amount of the civil | |
| penalty imposed in this proceeding. For purposes of this paragraph, a “Related Investor Action” | |
| means a private damages action brought against Respondent by or on behalf of one or more | |
| investors based on substantially the same facts as alleged in the Order instituted by the | |
| Commission in this proceeding. | |
| By the Commission. | |
| Brent J. Fields | |
| Secretary | |